ESR1 and breast cancer: Neuropeptide Y receptor 1 mediated the inhibitory effect of neuropeptide Y on estradiol-activated growth of estrogen receptor-positive BC cells, and the expression of neuropeptide Y receptor 1 has been suggested to be a biomarker to predict better survival and endocrine sensitivity in estrogen receptor-positive BC subjects [197].